Clinical trials: Microangiopathy
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy
The goal of this clinical trial is to evaluate the efficacy and safety of Iptacopan as a second-line treatment for high-risk hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA).
- Trial name
- NCT07347990
- Testing
- iptacopan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
SNAKEBITE, THROMBOTIC MICROANGIOPATHY
Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome
The aim of this study is to find the overall incidence of thrombotic microangiopathy in snakebite victims. As we know snakebite is a common in tropical regions.
- Conditions
- SNAKEBITE, THROMBOTIC MICROANGIOPATHY, SCHISTOCYTES
- Trial name
- NCT04845022
- Where
- India
- Volunteers
- 81 people
- Sponsor
- Jubilee Mission Medical College and Research Institute
Stroke, Cerebrovascular Accidents
Multimodal Retinal Imaging of Cerebrovascular Stroke
The hypothesis is that in patients with stroke, abnormalities of retinal microvascularization shown on color fundus photography and the depletion of retinal capillary density evaluated by OCT-A are markers of acute impairment of…
- Trial name
- OCTAV (NCT03964610)
- Testing
- color fundus photography (CFP) and OCT-A
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Thrombotic Microangiopathy, Disorder Related to Bone Marrow Transplantation
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
Mortality in the major thrombotic microangiopathies (TMAs), TTP and aHUS, exceeds 90% unless rapidly diagnosed and appropriately treated.
- Trial name
- NCT02604420
- Testing
- eculizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Weill Medical College of Cornell University
Thrombotic Microangiopathies
Defibrotide TMA Prophylaxis Pilot Trial
Thrombotic microangiopathy (TMA) is a common complication in the stem cell transplant population. Certain populations within the hematopoietic stem cell transplant (HSCT) population are at a higher risk than others.
- Trial name
- NCT03384693
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their…
- Trial name
- NCT04247906
- Testing
- Narsoplimab
- Sponsor
- Omeros Corporation
Non-proliferative Diabetic Retinopathy (NPDR), Diabetic Retinal Microangiopathy
A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy
This study aims to explore the preliminary clinical efficacy and safety of NPDR-01 eye drops in patients with non-proliferative diabetic retinopathy (NPDR).
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Diabetic Retinal Microangiopathy, Retinal Microaneurysms, Diabetic Retinopathy
- Trial name
- NCT07198815
- Testing
- Investigational Eye Drops (NPDR-01)
- Volunteers
- 10 people
- Sponsor
- Sichuan Academy of Medical Sciences
Diabetes Type 1
The MIND Study - Microangiopathy IN Diabetes
This clinical investigation will evaluate two contactless optical devices based on spatial frequency domain and laser speckle technology for quantification of the skin micro-circulation in patients with diabetes mellitus type 1.
- Trial name
- NCT06989190
- Where
- Sweden
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Thrombotic Microangiopathies
Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
Thrombotic microangiopathies (TMA) are defined as a triad combining mechanical hemolytic anemia, peripheral thrombocytopenia and ischemic organ damage.
- Trial name
- m-TMA (NCT06098378)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Thrombotic Microangiopathy
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
- Trial name
- NCT04543591
- Testing
- Ravulizumab, Best supportive care
- Where
- 66 sites in United States, Australia and 15 more
- Volunteers
- 148 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Thrombotic Microangiopathy, Acute Kidney Injury
French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
Thrombotic microangiopathies (TMAs) are a diverse, rare but serious group of diseases. Progress has been made regarding the epidemiology of TMA (Bayer CJASN 2019).
- Conditions
- Thrombotic Microangiopathy, Acute Kidney Injury, Hemolytic Uremic Syndrome, Nephrology
- Trial name
- MATRIX (NCT05991245)
- Testing
- Collecting datas
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Tours
Type2 Diabetes Mellitus, Complications
Morbidity in Newly Diagnosed type2 Diabetes in Adults
It is a prospective,observational, cohort study The main purpose of the study is to assess the prevalence of diabetic chronic complications in newly diagnosed type 2 diabetics in suburban area of Algiers.
- Trial name
- MORNDIAB (NCT02002091)
- Testing
- no specific treatment
- Where
- Algeria
- Volunteers
- 327 people
- Sponsor
- University of Algiers
Atypical Hemolytic Uremic Syndrome
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
The purpose of this Phase 3 study is to evaluate the efficacy and safety of iptacopan upon switching from anti-C5 antibody to iptacopan treatment in study participants with aHUS.
- Trial name
- NCT05935215
- Testing
- Iptacopan
- Where
- 31 sites in China, France and 6 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
The goal of this clinical trial is to learn about plasma biomarkers of diagnosed transplant-associated thrombotic microangiopathy (TA-TMA) in patients undergoing transplantation.
- Trial name
- NCT06102694
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Pre-Eclampsia, Severe, HELLP Syndrome
Promising Bimarker Prediction of Outcome of HELLP Syndrome.
HELLP syndrome is a life-threatening obstetric complication usually considered to be a variant or complication of pre-eclampsia.
- Conditions
- Pre-Eclampsia, Severe, HELLP Syndrome, Microangiopathy
- Trial name
- NCT03246542
- Testing
- shistocytes percentage
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AYMAN ABDELKADER MOHAMED ABDELKADER
Thrombotic Microangiopathies, Hemolytic Uremic Syndrome, Atypical
Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions.
- Conditions
- Thrombotic Microangiopathies, Hemolytic Uremic Syndrome, Atypical, Hemolytic-Uremic Syndrome
- Trial name
- COMPETE (NCT04745195)
- Where
- Netherlands
- Volunteers
- 42 people
- Sponsor
- Maastricht University Medical Center
Thrombotic Thrombocytopenic Purpura (TTP), Immune Thrombotic Thrombocytopenic Purpura
Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic organ damage due to microvascular thrombosis.
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP), Immune Thrombotic Thrombocytopenic Purpura, Thrombotic Microangiopathies, Microangiopathy, Thromboic
- Trial name
- TWILIGHT (NCT07205861)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetic Retinopathy
Prospective Cohort Study on Predicting the Progression of Diabetic Microangiopathy Using Multimodal Eye Imaging
To develop an artificial intelligence (AI) model to predict DR progression based on a prospective cohort database.With use of an innovative AI model and a validated machine learning algorithm, based on multimodal vascular and…
- Trial name
- NCT06727955
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Peking University Third Hospital
Thrombotic Microangiopathies
The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathy
Study rationale: Viral infections, such as CMV, are a risk factor for TA-TMA (transplantation-associated TMA). Viral infections increase interferon (IFN) levels and high IFN levels are associated with thrombotic microangiopathy…
- Trial name
- ROSARIO (NCT07705789)
- Testing
- blood draw, urine collection
- Where
- 3 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Sofie Dhaese
Type 2 Diabetes Mellitus, Microangiopathy
Changes in the Retinal and Carotid Microcirculation After Restoring Normoglycemia in Patients With Type 2 Diabetes
This is a prospective and observational study in patients with type two diabetes. The study hypothesis is that chronic hyperglycemia causes an increase in the microcirculation on the carotid artery wall and retina, evaluated by…
- Conditions
- Type 2 Diabetes Mellitus, Microangiopathy, Diabetic Retinopathy, Arteriosclerosis
- Trial name
- OCTAUS-T2D (NCT03594591)
- Testing
- Antidiabetic treatment by usual care
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Clinic of Barcelona